Lilly’s Foundayo Launch Triggers Fresh Buy rating Amid Strong Demand Forecasts

BMO Capital Markets reiterates a Buy-equivalent rating on Eli Lilly (LLY) with a $1,300 target as the obesity pill Foundayo rolls out. Lilly expects $1.5–$2.8 billion in U.S. sales this year and up to $36 billion in peak annual sales globally, with Foundayo distributed through Weight Watchers (WW) and Amazon among other channels. The FDA approved Foundayo on April 1, and Wall Street remains bullish, with a consensus Strong Buy from 19 analysts and an average target around $1,247, implying roughly 31% upside from current levels.